Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chronic Kidney Disease I: Introduction01:25

Chronic Kidney Disease I: Introduction

Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
Diabetic Nephropathy01:28

Diabetic Nephropathy

Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration occur due to afferent arteriolar...
Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration01:28

Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration

Glomerular filtration rate (GFR) can be estimated from serum creatinine using the modification of diet in renal disease (MDRD) formula or the chronic kidney disease–epidemiology collaboration (CKD–EPI) equation. Both methods are widely used in clinical practice to assess kidney function and guide treatment decisions.The MDRD equation does not require weight or height measurements and is normalized to the body surface area of 1.73 m², considered the average adult surface area. This equation is...
Acute Kidney Injury II: Pathophysiology01:29

Acute Kidney Injury II: Pathophysiology

Acute kidney injury (AKI) causes are categorized into three primary categories based on the location of the injury: prerenal, intrarenal (or intrinsic), and postrenal causes. This classification guides clinical management and illustrates how different pathways can impair kidney function.Etiology and Pathophysiology of Acute Kidney Injury1. Prerenal causesEtiology: Prerenal Acute Kidney Injury, the most common type, occurs when reduced blood flow to the kidneys decreases filtration capacity...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Banff 2024 Kidney Meeting Report: Rejection as a spectrum of phenotypes and focus on differential diagnostic reasoning.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2026
Same author

Role of lupus nephritis classification systems in everyday clinical practice: a questionnaire-based survey of the Renal Pathology Society (RPS).

Clinical kidney journal·2026
Same author

Shared multicellular injury programs of acute and chronic kidney disease enable mechanistic patient stratification.

medRxiv : the preprint server for health sciences·2026
Same author

Discoidin Domain Receptor 1 Translocation to the Mitochondria Promotes Oxidative Stress and Apoptosis in Acute Kidney Injury.

Journal of the American Society of Nephrology : JASN·2026
Same author

Signal Strength Aware Latent Spaces Reveal Molecularly Distinct Substructures within Human Kidney Tissue.

bioRxiv : the preprint server for biology·2026
Same author

Biomarkers of Lupus Nephritis Histopathology: Where Do We Stand?

Arthritis & rheumatology (Hoboken, N.J.)·2025

Related Experiment Video

Updated: Jun 10, 2026

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
07:15

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Published on: August 23, 2024

PPARγ and chronic kidney disease.

Agnes B Fogo1

  • 1MCN C3310, Department of Pathology, Vanderbilt University Medical Center, Nashville, TN 37232, USA. agnes.fogo@vanderbilt.edu

Pediatric Nephrology (Berlin, Germany)
|August 3, 2010
PubMed
Summary

Thiazolidinediones (TZDs), PPARγ agonists, show potential benefits for chronic kidney disease by modulating fibrotic and inflammatory pathways. Further research explores their effects beyond diabetes in kidney disease settings.

Area of Science:

  • Pharmacology
  • Nephrology
  • Endocrinology

Background:

  • Peroxisome proliferator-activated receptor-γ (PPARγ) agonists, like thiazolidinediones (TZDs), are established treatments for type 2 diabetes, improving insulin sensitivity and lipid metabolism.
  • PPARγ receptors, members of the nuclear receptor superfamily, regulate gene expression via PPAR response elements.
  • Emerging evidence suggests PPARγ agonists possess effects beyond metabolic regulation, impacting various cellular pathways.

Purpose of the Study:

  • To review the evidence for the therapeutic effects of TZDs in nondiabetic chronic kidney disease (CKD).
  • To explore the mechanisms by which PPARγ agonists may benefit kidney health in experimental and human CKD models.
  • To assess the impact of TZDs on fibrotic, inflammatory, immune, and oxidative stress pathways in CKD.

More Related Videos

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats
05:34

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats

Published on: April 4, 2025

Related Experiment Videos

Last Updated: Jun 10, 2026

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
07:15

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Published on: August 23, 2024

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats
05:34

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats

Published on: April 4, 2025

Main Methods:

  • Literature review of experimental studies and human clinical trials.
  • Analysis of research investigating the effects of PPARγ agonists on renal cells and pathways.
  • Focus on studies examining TZDs in nondiabetic CKD settings.

Main Results:

  • PPARγ agonists demonstrate pleiotropic effects in preclinical and clinical settings, extending beyond their known metabolic actions.
  • These agents modulate key pathogenic pathways in CKD, including renal fibrosis, inflammation, immune responses, and oxidative stress.
  • Evidence suggests potential renoprotective roles for TZDs in various forms of kidney disease.

Conclusions:

  • TZDs exhibit multifaceted therapeutic potential in chronic kidney disease, irrespective of diabetic status.
  • Their ability to target multiple fibrotic, inflammatory, and oxidative pathways presents a promising avenue for CKD management.
  • Further investigation into TZDs for nondiabetic CKD is warranted based on current evidence.